Other analysts have also recently issued research reports about the company. Zacks Investment Research cut Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 12th. HC Wainwright raised their price target on Dicerna Pharmaceuticals from $32.00 to $35.00 and gave the company a “buy” rating in a report on Friday, August 7th. B. Riley reiterated a “buy” rating and issued a $30.00 price target on shares of Dicerna Pharmaceuticals in a report on Monday, August 10th. ValuEngine upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 14th. Finally, SVB Leerink raised their price target on Dicerna Pharmaceuticals from $43.00 to $46.00 and gave the company an “outperform” rating in a report on Friday, August 7th. Two investment analysts have rated the stock with a sell rating and twelve have issued a buy rating to the company. Dicerna Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $34.27.
Shares of DRNA stock opened at $19.85 on Friday. The stock’s fifty day moving average is $19.18 and its 200-day moving average is $20.67. The stock has a market capitalization of $1.48 billion, a PE ratio of -11.21 and a beta of 1.56. Dicerna Pharmaceuticals has a 52 week low of $11.75 and a 52 week high of $27.68.
In other Dicerna Pharmaceuticals news, COO James B. Weissman sold 4,360 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $22.47, for a total transaction of $97,969.20. Following the transaction, the chief operating officer now owns 25,961 shares in the company, valued at $583,343.67. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Douglas Fambrough bought 10,000 shares of Dicerna Pharmaceuticals stock in a transaction on Tuesday, September 1st. The shares were bought at an average price of $18.06 per share, for a total transaction of $180,600.00. Following the acquisition, the chief executive officer now owns 22,300 shares of the company’s stock, valued at approximately $402,738. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 25,090 shares of company stock worth $614,541. Company insiders own 11.30% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in DRNA. FDx Advisors Inc. acquired a new stake in shares of Dicerna Pharmaceuticals during the first quarter worth about $38,000. US Bancorp DE raised its position in shares of Dicerna Pharmaceuticals by 147.9% during the first quarter. US Bancorp DE now owns 2,975 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 1,775 shares during the period. Macquarie Group Ltd. acquired a new stake in shares of Dicerna Pharmaceuticals during the second quarter worth about $62,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Dicerna Pharmaceuticals by 33.5% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,491 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 1,128 shares during the period. Finally, Advisors Asset Management Inc. acquired a new stake in shares of Dicerna Pharmaceuticals during the second quarter worth about $119,000. 83.50% of the stock is currently owned by institutional investors.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Featured Article: Price-Sales Ratio
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.